drugset / Trial / NCT03618355
Trial of eRapa in Prostate Cancer Patients
Phase 1
Completed
15 enrolled
Rapamycin Holdings, Inc. dba Emtora Biosciences
Cancer Insight, LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is to determine the safety, pharmacokinetics/pharmacodynamics, and immunologic impact of encapsulated rapamycin in patients with low risk prostate cancer under active surveillance. There will be four groups of patients, each receiving a different dose of rapamycin.
Timeline
- Start
- 2018-08-28
- Primary completion
- 2019-12-02
- Completion
- 2019-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 0.5 mg | Oral |
| Subject | Sirolimus | Small molecule | 1 mg | Oral |